TEVA Q1 2023 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.7B+0.0% YoY

Gross Profit

$1.6B43.2% margin

Operating Income

-$13M-0.4% margin

Net Income

-$220M-6.0% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

-5.7%

Cash Flow

Operating Cash Flow

-$145M

Free Cash Flow

-$284M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$43.5B

Total Liabilities

$34.8B

Stockholders' Equity

$7.9B

Cash & Equivalents

$2.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.7B	$3.7B	+0.0%
Gross Profit	$1.6B	$1.7B	-9.1%
Operating Income	-$13M	-$713M	+98.2%
Net Income	-$220M	-$955M	+77.0%

Revenue Segments

Product

$3.1B84%

Distribution Service

$434M12%

Product and Service, Other

$95M3%

License

$43M1%

Geographic Segments

North America Segment

$1.8B51%

Europe Segment

$1.2B34%

International Markets

$492M14%